Novo Nordisk A/S vs Target Corporation — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Target Corporation trades at $138.64 (market cap $63.40B). The key difference: Novo Nordisk A/S is far larger — about 3.5× Target Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | TGT | |
|---|---|---|
Market Cap | $220.53B | $63.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $71.70 | $141.19 |
52-Week Low | $35.29 | $83.68 |
Enterprise Value | $239.49B | $78.70B |
Dividend Yield | 3.63% | 3.32% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →